Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.98 |
| ▸ | TSPO | P30536 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL19581677 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL29527286 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL4589 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL8625 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL15005742 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL14672487 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL7607795 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL155760 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL5448036 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231775 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500241-B1 | COMBINATION THERAPY FOR COPD | CHIESI FARM SPA (IT) | 2023-10-04 | — | — | EP | claimed |
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| EP-3500241-A1 | COMBINATION THERAPY FOR COPD | Chiesi Farmaceutici S.p.A. (IT) | 2019-06-26 | — | — | EP | claimed |
| US-10098837-B2 | Combination therapy for COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-10-16 | — | — | US | claimed |
| WO-2018033598-A1 | COMBINATION THERAPY FOR COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-02-22 | — | — | WO | claimed |
| US-20180028439-A1 | COMBINATION THERAPY FOR COPD | CHIESI FARMACEUTICI S.P.A (IT) | 2018-02-01 | — | — | US | claimed |
| EP-4731184-A1 | A PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | Glenmark Pharmaceuticals Limited (IN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731184-A1 | A PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | Glenmark Pharmaceuticals Limited (IN) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026047392-A1 | A PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | GLENMARK SPECIALTY S.A. (CH) | 2026-03-05 | — | — | WO | disclosed |
| WO-2026047392-A1 | A PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | GLENMARK SPECIALTY S.A. (CH) | 2026-03-05 | — | — | WO | disclosed |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2001078736-A1 | MEDICAL COMBINATIONS COMPRISING TIOTROPIUM AND ROFLEPONIDE | GLAXO GROUP LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078736-A1 | MEDICAL COMBINATIONS COMPRISING TIOTROPIUM AND ROFLEPONIDE | GLAXO GROUP LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078739-A1 | MEDICAL COMBINATIONS COMPRISING TIOTROPIUM AND FLUTICASONE PROPRIONATE | GLAXO GROUP LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078741-A1 | MEDICAL COMBINATIONS COMPRISING TIOTROPIUM AND BUDESONIDE | GLAXO GROUP LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078741-A1 | MEDICAL COMBINATIONS COMPRISING TIOTROPIUM AND BUDESONIDE | GLAXO GROUP LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078739-A1 | MEDICAL COMBINATIONS COMPRISING TIOTROPIUM AND FLUTICASONE PROPRIONATE | GLAXO GROUP LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000047200-A1 | COMBINATIONS OF FORMOTEROL AND A TIOTROPIUM SALT | NOVARTIS AG (CH) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | CHRM3 2119/4885CHRM2 1517/4885CHRM1 1894/4885 |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | CHRM3 763/4885CHRM2 1244/4885CHRM1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.